More than just Covid: How Moderna plans to defeat cancer with AI and mRNA

Despite current operational losses, the company secures its future with a massive cash cushion of over $8 billion and aims for break-even by 2028 through strict cost discipline. To overcome dependence on volatile Covid revenues and the initially sluggish RSV launch, Moderna is fully focusing on the expected market introduction of the combined flu-Covid vaccine in 2026 as a new, stable revenue generator. The greatest market potential lies in the revolutionary personalized cancer vaccine (in partnership with Merck), with crucial study data to...